Neonci Technologies
Tracked across 3 events · 19 articles · First seen Apr 07, 2026 · Last active Aug 28, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Neonci Technologies has gained increased visibility and investor confidence due to new analyst coverage, significant insider buying, and expanding institutional ownership, ahead of key clinical trial milestones for its brain cancer therapies.
May 19, 2026 · 6 articles
Regulatory
Impact: Neonci Technologies received IND authorization for NEO212 from the United Arab Emirates — Department of Health – Abu Dhabi, marking its first international regulatory clearance. This approval creates an additional clinical development pathway outside the United States and is a significant milestone for the company's neuro-oncology programs.
Jun 16, 2026 · 6 articles
Business
Neonci Technologies reported positive topline results from its NEO100-01 Phase 2a study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The study met its primary endpoint with 48.9% six-month progression-free…
Impact: NeOnc is the central entity; positive Phase 2a results and planned FDA meeting could enhance its valuation and prospects, though approval is not guaranteed.
Aug 26, 2026 · 7 articles
100
Neonci Technologies reported positive resultsNeOnc NEO100 Phase 2a Results
90
Neonci Technologies plans to request United States — Food and Drug AdministrationNeOnc NEO100 Phase 2a Results
50
Neonci Technologies received IND approvals United Arab EmiratesNeOnc NEO100 Phase 2a Results
40
Amir Heshmatpour purchased shares Neonci TechnologiesNeOnc NEO100 Phase 2a Results
40
Thomas Chen purchased shares Neonci TechnologiesNeOnc NEO100 Phase 2a Results
ERGEN INTELLIGENCE
Track Neonci Technologies live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard